Aarti Drugs reported a strong Q2 FY27 performance with net profit rising 83.3% YoY to Rs 83 Cr and sales hitting Rs 826 Cr. Driven by improved margins and a favorable product mix, the company exceeded analyst estimates. Brokerage Axis Securities has upgraded the target price to Rs 610, highlighting robust operational efficiency and expansion plans in the API and oncology segments.
Aarti Drugs Q2 FY27 Net Profit Climbs 83% to Rs 83 Cr
Net Sales Surge 26.6% YoY to Rs 826 Cr
Reader Takeaway: Strong operational gains and backward integration drive earnings, but watch for potential input cost volatility.